Cleared Traditional

HemoSphere Advanced Monitor, HemoSphere Tissue Oximetry Module (K190205) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K190205 · Edwards Lifesciences, LLC · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2019
Decision
206d
Days
Class 2
Risk

K190205 is an FDA 510(k) clearance for the HemoSphere Advanced Monitor, HemoSphere Tissue Oximetry Module. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Edwards Lifesciences, LLC (Irvine, US). The FDA issued a Cleared decision on August 29, 2019 after a review of 206 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Edwards Lifesciences, LLC devices

Submission Details

510(k) Number K190205 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 04, 2019
Decision Date August 29, 2019
Days to Decision 206 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
81d slower than avg
Panel avg: 125d · This submission: 206d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 183
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K190205.
AcQMap High Resolution Imaging and Mapping System
K193013 · Acutus Medical, Inc. · Feb 2020
Rhythmia HDxTM Mapping System
K192438 · Boston Scientific Corporation · Nov 2019
AcQMap High Resolution Imaging and Mapping System
K191392 · Acutus Medical, Inc. · Sep 2019
Zio XT ECG Monitoring System, Zio AT ECG Monitoring System
K190593 · iRhythm Technologies, Inc. · Aug 2019
CARTO 3 EP Navigation System, Version 7.1 and Accessories
K191660 · Biosense Webster, Inc. · Jul 2019
iLab Polaris Multi-Modality Guidance System
K191008 · Boston Scientific Corporation · Jul 2019